We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Gracie Lieberman is a Biostatistician with 30+ years of experience in oncology clinical trials. Gracie is a Director of Regulatory Policy at Genentech and one of her focus areas is utilization of Real World Data in regulatory decision-making.
During the first 8 years of her professional career, Gracie worked at the Institute of Tuberculosis and Pulmonary Diseases in Warsaw, Poland, where she assisted surgeons and oncologists collect, analyze and interpret data from lung cancer trials. In this setting, she had the privilege to participate in the daily rounds, meet patients and observe their struggles.
For the past 24 years at Genentech, Gracie has gained experience in all phases of drug development, from pre-IND to post-marketing, drug/diagnostic co-development, and collection/evaluation of Patient Reported Outcomes (PROs). Gracie served on review and oversight committees, advising and guiding molecule development teams and participated in select strategic initiatives such as 2NME Development Considerations. She also led a Biostatistics Initiative on Drug/Diagnostic Co-Development.
Gracie has a Master’s Degree in Biostatistics from the University of North Carolina at Chapel Hill.
This speaker's sessions: